Form 4: Esperion Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Esperion Therapeutics CEO Sheldon L. Koenig sold 12,447 shares of common stock on December 17, 2024, to satisfy tax obligations related to vested restricted stock units.
Summary
- On December 17, 2024, Sheldon L. Koenig, the President and CEO of Esperion Therapeutics, Inc., sold 12,447 shares of common stock.
- The sale was executed at a price of $2.466 per share.
- The transaction was conducted to cover tax obligations arising from the vesting of restricted stock units.
- Following the transaction, Koenig directly owns 739,819 shares of Esperion Therapeutics, Inc.
Sentiment
Score: 6
Explanation: The document is a standard SEC filing related to a stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment about the company's performance.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation and are not necessarily indicative of a negative outlook on the company's future.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 12/17/2024 | Date of the stock sale transaction. |
| 12/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.